Alnylam Is Down 30%: Buy the Rare-Gene Leader or Fade a Guidance Trap?

Why Alnylam's 30% pullback changed the story

Alnylam has lost nearly 30% of its stock value, along with close to $12 billion in market capitalization. The company is no longer trading as a straightforward growth story. It is trading as a debate over whether the market is overreacting to a reset or finally pricing in a slower phase of growth.

The catalyst was a direct guidance reset. Management cut its transthyretin amyloidosis franchise outlook to $4.2 billion to $4.5 billion from $4.4 billion to $4.7 billion and said pent-up demand has normalized. That matters because investors had been modeling a steeper launch curve. Management just changed the shape of that curve.

The reset also arrived in a second-quarter earnings report that did little to ease investor worries in an already challenging year. That helps explain why the stock reaction was so sharp: the business still looked credible, but the growth path was revised lower just as investors were questioning how much of the original outlook was already priced in.

Why EPS did not stop the selloff

Alnylam reported Q2 adjusted EPS of $1.84, ahead of the $1.55 consensus. But revenue was $1.29 billion, below the $1.323 billion expected. For a stock tied to launch momentum, that top-line miss mattered more than the earnings beat.

Management's comment that pent-up demand has normalized shifted the market's focus. Investors were no longer asking only whether demand existed. They were asking how quickly that demand converts into revenue after the initial backlog clears.

Amvuttra started fast, so the reset hit harder

The core issue sits in the flagship franchise. Alnylam reported Q2 global net product revenue of $1.012 billion for Amvuttra and $18 million for Onpattro, after Q1 net product revenues of $1.036 billion. Those are strong numbers, but they also make the normalization argument more plausible to the market. After such a fast start, investors were primed for continued acceleration. Instead, management suggested part of the early strength came from satisfying waiting patients.

That helps explain the multiple compression. The problem was not collapse so much as re-anchoring: investors now have to value Amvuttra less like a straight-line blockbuster and more like a successful launch moving into steadier demand.

Competition makes TTR a share debate

The reset also landed in a more competitive ATTR-CM landscape. Alnylam is now defending its position against a broader treatment debate that includes Pfizer's Vyndamax, BridgeBio's Attruby, and eplontersen. That makes the franchise less of a clean monopoly story and more of an execution and share story.

What changed: - The growth curve appears flatter after backlog clearance. - The market now cares more about sustained performance than early momentum. - Competition and treatment-sequence questions matter more.

Why some investors still see an opportunity

The growth engine still looks intact

The key question is whether Alnylam lost some early excess or lost its engine. The Q1 results still support the first view. First-quarter net product revenue grew 121% compared with Q1 2025, and TTR revenue grew 153%. Even after management said pent-up demand has normalized, that does not by itself prove a lower peak sales ceiling.

The broader guidance framework was not wiped out either. In April, Alnylam reiterated 2026 combined net product revenue guidance of $4.9 billion to $5.3 billion. After the later reset, the company still pointed to a 2026 sales range of $5.275 billion to $5.725 billion. With the stock around $205.58, that leaves room for a rerating if the next few quarters show TTR growth stabilizing rather than weakening structurally.

Analyst optimism has not followed the stock

Wall Street's stance still looks unusually constructive compared with the share price. The stock market data shows $205.58 after a sharp session, alongside a consensus rating built on 76 buy ratings, 16 hold ratings, and 0 sell ratings. That does not guarantee the stock is cheap, but it does suggest many analysts still see a stronger long-term path than the recent price action implies.

For investors leaning bullish, the real proof points are stable TTR run-rate growth and less pressure from the competitive and treatment-sequence debate. Those would matter more than another quarter of emotional repricing.

What the next 90 days need to show

After the guidance cut, the next reporting window matters less as a new valuation formula and more as a test of whether this is normalization or a slower regime.

How to read the setup

Treat Alnylam as a prove-it opportunity rather than an automatic buy. The franchise is only compelling if the next quarter shows steadier demand rather than another step down. The key evidence is already being watched closely: management linked the reset to pent-up demand, while traders are focused on upcoming pipeline catalysts and competitor dynamics in ATTR-CM.

Signals that matter

Bullish normalization signals - The franchise stabilizes after the normalization narrative instead of producing another downgrade. - Late-August ATTR data reduces, rather than expands, the eplontersen overhang. - Second-half pipeline progress supports the idea that TTR is the main engine, not the entire story, consistent with clinical readouts during the second half of 2026.

Bearish trap signals - Another soft revenue quarter keeps the market focused on top-line misses. - Competition and treatment-sequence debate intensify, exactly what traders say they are now watching after the guidance revision. - Concerns deepen instead of easing after the second-quarter earnings report did little to assuage investor concerns.

If the next few catalysts reduce uncertainty around competition and demand normalization, the selloff could look more like an overreaction. If they do not, the market may be right to view Alnylam as a slower, more contested share fight than many investors originally expected.